Takeda Offers Shire Asset Disposal To Assuage EC Merger Concerns
Takeda may have to shed a Shire late-stage pipeline asset to meet European anti-competition concerns around the companies' planned merger, although the process is not expected to derail the deal's timing.
You may also be interested in...
European Commission gives an expected conditional regulatory approval for the acquisition of Shire by Takeda, removing the last potential antitrust hurdle to the deal, meaning that attention is now turning to the upcoming shareholders' meetings that would open the final path to the early January completion of the record-setting transaction.
Takeda is hoping to start 2019 with a bang, saying its huge acquisition of Shire might become a done deal as early as January 8. Speculation continues meanwhile on possible post-merger divestments to help pay down associated debt.
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.